← Eichor
Condition: Amyloidosis Systemic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Amyloidosis Systemic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch
Phase 1/Phase 2 · 23 location(s) · AbbVie · NCT06158854Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an
Phase 2 · 5 location(s) · GlaxoSmithKline · NCT07224672[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
Phase N/A · 2 location(s) · Tianjin Medical University · NCT07232459Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07448779Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagn
Phase 3 · 117 location(s) · SWOG Cancer Research Network · NCT06022939A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 · 2 location(s) · Mayo Clinic · NCT05898646A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREK
Phase N/A · 6 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06205953Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559The Norwegian Immunotherapy in Multiple Myeloma Study
Phase N/A · 23 location(s) · St. Olavs Hospital · NCT06855121Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Phase 2 · 1 location(s) · Oregon Health and Science University · NCT05758493Essen Amyloidosis Registry
Phase N/A · 1 location(s) · University Hospital, Essen · NCT06887283Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis
Phase 1/Phase 2 · 27 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07266116A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Phase 1 · 1 location(s) · University of Tennessee Graduate School of Medicine · NCT05951816Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
NA · 2 location(s) · Peking University People's Hospital · NCT06699394Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi
Phase 1 · 9 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT07250269Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Clinical Study for AL-CM
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04924998A Prospective Cohort Study on Primary Cutaneous Amyloidosis
Phase 4 · 1 location(s) · Army Medical University, China · NCT06998875A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335The Italian Transthyretin Amyloidosis Web-Network
Phase N/A · 30 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT05444920Teclistamab in Previously Treated AL Amyloidosis
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06935162Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07626476Daratumumab for Patients With Light Chain Amyloidosis
NA · 1 location(s) · Nanjing University School of Medicine · NCT063762143'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06866912Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Phase 2 · 1 location(s) · Jin Lu, MD · NCT06342466Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Phase 2 · 3 location(s) · Peking University People's Hospital · NCT06418477A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07638683
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.